申请人:Bromidge M Steven
公开号:US20050154028A1
公开(公告)日:2005-07-14
Compounds of formula (I) or a pharmaceutically acceptable salt thereof, having 5HT
2C
receptor activity, are disclosed: wherein a is 0,1,2,3,4 or 5; b is 1,2 or 3; Y is nitrogen or carbon; A is oxygen, nitrogen, —CONH—, —NHCO— or together with R
2
form a benzoxazolone group; R
1
is halogen, C
1-6
alkyl, C
1-6
alkoxy, C
1-6
alkylthio, hydroxy, amino, mono- or di-C
1-6
alkylamino, nitro, CN, CF
3
, OCF
3
, aryl, arylC
1-6
alkyl, arylC
1-6
alkyloxy or arylC
1-6
alkylthio; R
2
is hydrogen, halogen, C
1-6
alkyl, C
1-6
alkoxy, haloC
1-6
alkyl or haloC
1-6
alkoxy; R
3
is: (i) —NR
4
R
5
where R
4
and R
5
are independently hydrogen, C
1-6
alkyl or arylC
1-6
alkyl; or (ii) an optionally substituted N-linked heterocycle; or (iii) an optionally substituted C-linked heterocycle; ======= is a single bond or a double bond; and X is CH
2
or C═O (when ======= is a single bond) or X is CH (when ======= is a double bond). The preparation of these compounds and their use in therapy, especially for a CNS disorder such as depression or anxiety, are also disclosed.
公开了式(I)化合物或其药学上可接受的盐,具有5HT2C受体活性:其中a为0、1、2、3、4或5;b为1、2或3;Y为氮或碳;A为氧、氮、-CONH-、-NHCO-或与R2一起形成苯并噁唑酮基团;R1为卤素、C1-6烷基、C1-6烷氧基、C1-6烷基硫基、羟基、氨基、单-或双C1-6烷基氨基、硝基、CN、CF3、OCF3、芳基、芳基C1-6烷基、芳基C1-6烷氧基或芳基C1-6烷硫基;R2为氢、卤素、C1-6烷基、C1-6烷氧基、卤代C1-6烷基或卤代C1-6烷氧基;R3为:(i)-NR4R5,其中R4和R5独立地为氢、C1-6烷基或芳基C1-6烷基;或(ii)可选地取代的N-连接杂环;或(iii)可选地取代的C-连接杂环;=======为单键或双键;X为CH2或C═O(当=======为单键时)或X为CH(当=======为双键时)。还公开了这些化合物的制备及其在治疗中的使用,特别是用于中枢神经系统障碍,如抑郁症或焦虑症。